Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 6/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.84 |
| ▸ | NT5E | P21589 | 1/20 | 0.84 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.80 |
| ▸ | SRC | P12931 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.80 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.80 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.80 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.80 |
| ▸ | LDHA | P00338 | 1/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.80 |
| ▸ | FBP1 | P09467 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphosphomethylphosphonic Acid Adenosyl Ester SCHEMBL2345274 | 1.00 | ENPP1 (1.00) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL18351578 | 0.95 | ENPP1 (0.92) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL16674879 | 0.95 | ENPP1 (0.92) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL22918310 | 0.93 | ENPP1 (1.00) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL21362894 | 0.93 | ENPP1 (1.00) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL21362946 | 0.93 | ENPP1 (0.86) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL16351392 | 0.93 | ENPP1 (1.00) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL16351407 | 0.92 | ENPP1 (0.85) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL29941042 | 0.92 | ENPP1 (0.90) | ENPP1P2RX1P2RX3TSHRKDM4E | |
| SCHEMBL16674886 | 0.92 | P2RX1 (0.93) | ENPP1P2RX1P2RX3TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709357-A2 | EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12569507-B2 | CAR T-cells for the treatment of bone metastatic cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260029388-A1 | COMPOUNDS FOR USE IN SYSTEM SUITABILITY TESTING OF INERT LC SYSTEMS AND COLUMNS | WATERS TECHNOLOGIES CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| US-12503470-B2 | Preparation of a P2X3 antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| US-12461078-B2 | Compounds for use in system suitability testing of inert LC systems and columns | WATERS TECHNOLOGIES CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4213999-B1 | KIT FOR USE IN SYSTEM SUITABILITY TESTING OF INERT LC SYSTEMS AND COLUMNS | WATERS TECHNOLOGIES CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119790042-A | Preparation of P2X3 antagonists | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| CN-116157679-B | Compounds for system suitability testing of inert liquid chromatography systems and columns | 沃特世科技公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4103572-A1 | PREPARATION OF A P2X3 ANTAGONIST | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | disclosed |
| EP-4055018-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054559-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-115011627-A | Preparation method of cotton bollworm-resistant transgenic cotton | 新疆大学 | 2022-09-06 | — | — | CN | disclosed |
| US-20220220552-A1 | METHODS FOR DIRECT SEQUENCING OF RNA | NEW YORK INSTITUTE OF TECHNOLOGY | 2022-07-14 | — | — | US | disclosed |
| WO-2022137126-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOLID TUMORS | POLYPID LTD. (IL) | 2022-06-30 | — | — | WO | disclosed |
| CN-114551996-A | Cyclophosphnitrile modified flame-retardant polymer electrolyte and preparation method thereof | 福州大学 | 2022-05-27 | — | — | CN | disclosed |
| US-20220160724-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| WO-2022058858-A1 | COMPOUNDS FOR USE IN SYSTEM SUITABILITY TESTING OF INERT LC SYSTEMS AND COLUMNS | WATERS TECHNOLOGIES CORPORATION (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220091079-A1 | COMPOUNDS FOR USE IN SYSTEM SUITABILITY TESTING OF INERT LC SYSTEMS AND COLUMNS | WATERS TECHNOLOGIES CORPORATION (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569507-B2 | CAR T-cells for the treatment of bone metastatic cancer | ICOS, CD47, CD4 | ENPP1 550/4885P2RX1 249/4885P2RX3 190/4885 |
| US-20260029388-A1 | COMPOUNDS FOR USE IN SYSTEM SUITABILITY TESTING OF INERT LC SYSTEMS AND COLUMNS | KIT, SLC6A4, SLC6A6 | ENPP1 3200/4885P2RX1 69/4885P2RX3 65/4885 |
| US-12503470-B2 | Preparation of a P2X3 antagonist | P2RX3, P2RX4, P2RX7 | ENPP1 742/4885P2RX1 5/4885P2RX3 1/4885 |
| US-20220160724-A1 | SELECTIVE P2X3 MODULATORS | P2RX3, P2RX2, P2RX4 | ENPP1 1074/4885P2RX1 4/4885P2RX3 1/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | ENPP1 111/4885P2RX1 3/4885P2RX3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.